Neuronetics Wins 2023 Bell Seal for Workplace Mental Health
15 Maio 2023 - 9:56AM
Neuronetics, Inc. (NASDAQ: STIM), a medical technology company
focused on designing, developing, and marketing products that
improve the quality of life for patients who suffer from
neurohealth disorders, announced today that it has been awarded the
Silver Bell Seal for Workplace Mental Health by Mental Health
America (MHA).
“We are incredibly grateful and humbled to be recognized by
MHA,” said Keith J. Sullivan, President and CEO of Neuronetics. “As
a company committed to improving people’s lives, we know that
extends to our own people. Creating a workplace that provides our
employees with a healthy environment, fosters comradery, and
prioritizes emotional well-being is crucial to the success of our
Company and the customers and patients we serve. Our HR team has
worked tirelessly to create programs, resources, and benefits that
bring this to life for our team.”
Founded in 1909, MHA is the nation’s leading community-based
nonprofit dedicated to addressing the overall mental health of all
and has spent decades researching it in the workplace. In 2019, MHA
introduced the Bell Seal for Workplace Mental Health, the
first-of-its-kind certification that recognizes employers who
strive to improve employees’ well-being and create a
psychologically safe workplace for all.
"This recognition is a testament to our team's dedication in
creating a supportive and nurturing workplace culture that
prioritizes mental health," said Kara Thornton, Sr. Vice President
of Human Resources at Neuronetics. "We stand with our employees in
the fight against stigma and will continue delivering resources
that maintain this standard of excellence set by MHA."
Major depressive disorder (MDD) is a serious issue that affects
21 million adults in the United States, with 6.4 million people
being underserved by antidepressant medication. The Company’s
NeuroStar Advanced Therapy for Mental Health is a non-drug
treatment that can help alleviate the burden of
medication-resistant depression using non-invasive TMS
(transcranial magnetic stimulation). For more information about
Neuronetics or NeuroStar, please visit neurostar.com.
About NeuroneticsNeuronetics,
Inc. believes that mental health is as important as physical
health. As a global leader in
neuroscience, Neuronetics is redefining patient and
physician expectations with its NeuroStar Advanced Therapy for
Mental Health. NeuroStar is a non-drug, noninvasive treatment that
can improve the quality of life for people suffering from
neurohealth conditions when traditional medication hasn’t helped.
NeuroStar is FDA-cleared for adults with major depressive disorder
(MDD), as an adjunct for adults with obsessive-compulsive disorder
(OCD), and to decrease anxiety symptoms in adult patients with MDD
that may exhibit comorbid anxiety symptoms (anxious depression).
NeuroStar Advanced Therapy is the leading transcranial magnetic
stimulation (TMS) treatment for MDD in adults with over 5.4 million
treatments delivered. NeuroStar is backed by the largest clinical
data set of any TMS system for depression, including the world’s
largest depression Outcomes Registry. Neuronetics is
committed to transforming lives by offering an exceptional
treatment that produces extraordinary results. For safety and
prescribing
information, www.neurostar.com.
Media
Contact:EvolveMKD646.517.4220NeuroStar@evolvemkd.com
Neuronetics (NASDAQ:STIM)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Neuronetics (NASDAQ:STIM)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024